Abstract:Human immunodeficiency virus type 1 (HIV-1) entry into the host cell involves a cascade of events and currently represents one of most attractive targets in the search for new antiviral drugs. The fusion-active gp41 core structure is a stable six-helix bundle (6-HB) folded by its trimeric N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR). Peptides derived from the CHR region of HIV-1 gp41 are potent fusion inhibitors that target the NHR to block viral and cellular membrane fusion in a dominant negative fashion. However, all CHR peptides reported to date are derived primarily from residues 628 to 673 of gp41; little attention has been paid to the upstream sequence of the pocket binding domain (PBD) in the CHR. Here, we have identified a Motif ((621)QIWNNMT(627)) located at the upstream region of the gp41 CHR, immediately adjacent to the PBD ((WMEWEREI635)-W-628). Biophysical characterization demonstrated that this motif is critical for the stabilization of the gp41 6-HB core. The peptide CP621-652, containing the (621)QIWNNMT(627) motif, was able to interact with T21, a counterpart peptide derived from the NHR, to form a typical 6-HB structure with a high thermostability (thermal unfolding transition [T-m] value of 82 degrees C). In contrast, the 6-HB formed by the peptides N36 and C34, which has been considered to be a core structure of the fusion-active gp41, had a T-m of 64 degrees C. Different from T-20 (brand name Fuseon), which is the first and only HIV-1 fusion inhibitor approved for clinical use, CP621-652 could efficiently block 6-HB formation in a dose-dependent manner. Significantly, CP621-652 had potent inhibitory activity against HIV-1-mediated cell-cell fusion and infection, especially against T-20- and C34-resistant virus. Therefore, our works provide important information for understanding the core structure of the fusion-active gp41 and for designing novel anti-HIV peptides.

Mutations of Gln64 in the HIV-1 Gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the Gp41 Pocket

ST103 HIV-1 Variants with Mutations in the Gp41 Pocket Region Are Resistant to HIV Fusion Inhibitors with Pocket-Binding Domain, but Sensitive to T20

HIV-1 Variants with a Single-Point Mutation in the Gp41 Pocket Region Exhibiting Different Susceptibility to HIV Fusion Inhibitors with Pocket- or Membrane-Binding Domain.

Hydrophobic Mutations In Buried Polar Residues Enhance Hiv-1 Gp41 N-Terminal Heptad Repeat-C-Terminal Heptad Repeat Interactions And C-Peptides' Anti-Hiv Activity

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Correction: HIV-1 Fusion is Blocked Through Binding of GB Virus C E2D Peptides to the HIV-1 Gp41 Disulfide Loop.

Helical Interactions in the HIV-1 Gp41 Core Reveal Structural Basis for the Inhibitory Activity of Gp41 Peptides.

HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.

Identification Of A Critical Motif For The Human Immunodeficiency Virus Type 1 (Hiv-1) Gp41 Core Structure: Implications For Designing Novel Anti-Hiv Fusion Inhibitors

Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors

Conserved Residue Lys574 in the Cavity of HIV-1 Gp41 Coiled-coil Domain is Critical for Six-helix Bundle Stability and Virus Entry*

An Artificial Peptide-Based Hiv-1 Fusion Inhibitor Containing M-T Hook Structure Exhibiting Improved Antiviral Potency and Drug Resistance Profile

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket

Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion.

Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.

The Conserved Residue Arg46 in the N-Terminal Heptad Repeat Domain of HIV-1 Gp41 is Critical for Viral Fusion and Entry

A Comparative Insight into Amprenavir Resistance of Mutations V32i, G48v, I50v, I54v, and I84v in Hiv-1 Protease Based on Thermodynamic Integration and Mm-Pbsa Methods

Design, Synthesis and Activity Evaluation of Novel Peptide Fusion Inhibitors Targeting HIV-1 Gp41

Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket

Approaches for Identification of HIV-1 Entry Inhibitors Targeting Gp41 Pocket.

Some Insights into Mechanism for Binding and Drug Resistance of Wild Type and I50V V82A and I84V Mutations in HIV-1 Protease with GRL-98065 Inhibitor from Molecular Dynamic Simulations.